Literature DB >> 27378569

Serum free thiols in chronic heart failure.

Anne M Koning1, Wouter C Meijers2, Andreas Pasch3, Henri G D Leuvenink4, Anne-Roos S Frenay5, Marinda M Dekker5, Martin Feelisch6, Rudolf A de Boer2, Harry van Goor7.   

Abstract

Oxidative stress is a key element of the pathophysiology of heart failure (HF). As free thiols are readily oxidized by reactive oxygen and sulfur species, their circulating level may directly reflect the systemic redox status. This study addresses the role of serum free thiols in chronic HF, which is of particular interest as free thiols are amenable to therapeutic modulation and thus are a potential target for therapy. Free thiols were measured in serum of 101 previously characterized stable chronic HF patients (93% male, age 63.7±10.0y, left ventricular ejection fraction 34.6±8.2%), adjusted for total serum protein, and subsequently analysed for associations with clinical and outcome parameters. The mean serum free thiol concentration was 3.6±0.5μM/g protein. Patients with above-average levels were younger, had better renal function, lower levels of NT-proBNP and PTH, and higher levels of cholesterol. Furthermore, above-average levels were associated with favourable disease outcome, i.e. a decreased rehospitalisation rate and increased patient survival (HR 0.27 (95% CI 0.11-0.62), P=0.002) independent of associated clinical parameters, age and PTH. After adjustment for cholesterol or established prognostic factors in HF, eGFR and NT-proBNP the association was no longer significant, suggesting involvement of these variables in a common pathophysiological pathway. This exploratory study demonstrates favourable associations of serum free thiols with markers of HF severity and prognosis as well as disease outcome, which should be further investigated in larger prospective studies. Restoring redox status by therapeutic modulation of free thiols may be a promising strategy to improve disease outcome in CHF.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic heart failure; Oxidative stress; Redox status; Rehospitalisation; Survival; Thiols

Mesh:

Substances:

Year:  2016        PMID: 27378569     DOI: 10.1016/j.phrs.2016.06.027

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  29 in total

Review 1.  The Reactive Species Interactome: Evolutionary Emergence, Biological Significance, and Opportunities for Redox Metabolomics and Personalized Medicine.

Authors:  Miriam M Cortese-Krott; Anne Koning; Gunter G C Kuhnle; Peter Nagy; Christopher L Bianco; Andreas Pasch; David A Wink; Jon M Fukuto; Alan A Jackson; Harry van Goor; Kenneth R Olson; Martin Feelisch
Journal:  Antioxid Redox Signal       Date:  2017-06-06       Impact factor: 8.401

2.  Plasma Free Thiol Levels during Early Sepsis Predict Future Renal Function Decline.

Authors:  Elisabeth C van der Slikke; Lisanne Boekhoud; Arno R Bourgonje; Tycho J Olgers; Jan C Ter Maaten; Robert H Henning; Harry van Goor; Hjalmar R Bouma
Journal:  Antioxidants (Basel)       Date:  2022-04-19

3.  Systemic Oxidative Stress, Aging and the Risk of Cardiovascular Events in the General Female Population.

Authors:  Martin F Bourgonje; Arno R Bourgonje; Amaal E Abdulle; Lyanne M Kieneker; Sacha la Bastide-van Gemert; Ron T Gansevoort; Stephan J L Bakker; Douwe J Mulder; Andreas Pasch; Jumana Saleh; Sanne J Gordijn; Harry van Goor
Journal:  Front Cardiovasc Med       Date:  2021-02-09

4.  Oxidative stress is associated with suspected non-alcoholic fatty liver disease and all-cause mortality in the general population.

Authors:  Turtushikh Damba; Arno R Bourgonje; Amaal E Abdulle; Andreas Pasch; Svenja Sydor; Eline H van den Berg; Ron T Gansevoort; Stephan J L Bakker; Hans Blokzijl; Robin P F Dullaart; Harry van Goor; Han Moshage
Journal:  Liver Int       Date:  2020-06-28       Impact factor: 5.828

5.  Riboflavin Supplementation in Patients with Crohn's Disease [the RISE-UP study].

Authors:  Julius Z H von Martels; Arno R Bourgonje; Marjolein A Y Klaassen; Hassan A A Alkhalifah; Mehdi Sadaghian Sadabad; Arnau Vich Vila; Ranko Gacesa; Ruben Y Gabriëls; Robert E Steinert; Bernadien H Jansen; Marian L C Bulthuis; Hendrik M van Dullemen; Marijn C Visschedijk; Eleonora A M Festen; Rinse K Weersma; Paul de Vos; Harry van Goor; Klaas Nico Faber; Hermie J M Harmsen; Gerard Dijkstra
Journal:  J Crohns Colitis       Date:  2020-06-19       Impact factor: 9.071

6.  Serum free thiols in type 2 diabetes mellitus: A prospective study.

Authors:  Emmelien E M Schillern; Andreas Pasch; Martin Feelisch; Femke Waanders; Steven H Hendriks; Rik Mencke; Geert Harms; Klaas H Groenier; Henk J G Bilo; Jan-Luuk Hillebrands; Harry van Goor; Peter R van Dijk
Journal:  J Clin Transl Endocrinol       Date:  2019-02-28

7.  Rapid free thiol rebound is a physiological response following cold-induced vasoconstriction in healthy humans, primary Raynaud and systemic sclerosis.

Authors:  Amaal Eman Abdulle; Anniek M van Roon; Andries J Smit; Andreas Pasch; Matijs van Meurs; Hendrika Bootsma; Stephan J L Bakker; Mohammad Y Said; Bernadette O Fernandez; Martin Feelisch; Harry van Goor; Douwe J Mulder
Journal:  Physiol Rep       Date:  2019-03

8.  Reactive Species Interactome Alterations in Oocyte Donation Pregnancies in the Absence and Presence of Pre-Eclampsia.

Authors:  Manon Bos; Mirthe H Schoots; Bernadette O Fernandez; Monika Mikus-Lelinska; Laurie C Lau; Michael Eikmans; Harry van Goor; Sanne J Gordijn; Andreas Pasch; Martin Feelisch; Marie-Louise P van der Hoorn
Journal:  Int J Mol Sci       Date:  2019-03-06       Impact factor: 5.923

9.  Relaxin Inhibits Ventricular Arrhythmia and Asystole in Rats With Pulmonary Arterial Hypertension.

Authors:  Brian Martin; Rebecca R Vanderpool; Brian L Henry; Joshua B Palma; Beth Gabris; Yen-Chun Lai; Jian Hu; Stevan P Tofovic; Rajiv P Reddy; Ana L Mora; Mark T Gladwin; Guillermo Romero; Guy Salama
Journal:  Front Cardiovasc Med       Date:  2021-07-06

10.  Influence of SGLT2 Inhibitor Treatment on Urine Antioxidant Status in Type 2 Diabetic Patients: A Pilot Study.

Authors:  Diana Nabrdalik-Leśniak; Katarzyna Nabrdalik; Katarzyna Sedlaczek; Patryk Główczyński; Hanna Kwiendacz; Tomasz Sawczyn; Weronika Hajzler; Karolina Drożdż; Mirela Hendel; Krzysztof Irlik; Paweł Stelmach; Piotr Adamczyk; Andrzej Paradysz; Sławomir Kasperczyk; Tomasz Stompór; Janusz Gumprecht
Journal:  Oxid Med Cell Longev       Date:  2021-07-14       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.